SUO 2018: Clinicopathologic Correlates of Copy Number Variations in Clear Cell Renal Cell Carcinoma: A Study of 178 Samples Profiled with Next-generation Sequencing

Phoenix, Arizona ( Renal cell carcinoma (RCC) was once viewed as a single and distinct solid organ malignancy, but is now understood to represent a diverse group of tumors arising from a common source. Contemporary sequencing studies have shed light on a diverse group of cancers with varying genetic blue prints.

SUO 2018: A Statistical Analyses of the PROSPER Study by Prior Definitive Surgery

Phoenix, Arizona ( Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) are at high risk of developing metastatic CRPC. Metastases development is associated with rising PSA and PSA doubling time of less than 10 months. Therefore, the goal of nmCRPC treatment is to delay metastatic disease progression, delay initiation of additional antineoplastic therapies, and thus prolong survival with maximizing the quality of life. Enzalutamide has been shown to be superior to bicalutamide in improving radiographic progression free survival in a subgroup of patients with nmCRPC in the STRIVE trial.1 

SUO 2018: Renal Biopsy Cell Cycle Proliferation (CCP) Score Predicts Adverse Surgical Pathology in Renal Cell Carcinoma

Phoenix, Arizona ( The role of renal mass biopsy (RMB) has significantly expanded in the last decade in an attempt to improve the risk stratification of patients given the variability in malignant risk. With recent improvements in image-guided equipment and technique, RMB is safe and associated with improved diagnostic yield (∼90%), but its ability to accurately assess tumor grade and adverse pathology is still limited.

SUO 2018: Combination Chemotherapy-Immunotherapy for Bladder Cancer

Phoenix, Arizona ( Dr. William Tabayoyong, a Society of Urologic Oncology Fellow at MD Anderson Cancer Center wrapped up the 2018 annual meeting of the Society of Urologic Oncology by giving a research scholar’s update on his translational work looking at combination chemoimmunotherapy in patients with muscle invasive bladder cancer (MIBC).

SUO 2018: European Section Oncology-Urology (ESOU) Lecture: Radical Cystectomy in the Octogenarian

Phoenix, Arizona ( Historically, radical cystectomy was rarely offered to octogenarian patients due to concerns of high rates of perioperative morbidities, as well as rather high 90-day mortality rates. Dr. Maurizio Brausi from Modena, Italy was the invited European Section Oncology-Urology (ESOU) lecturer at the 2018 Society of Urologic Oncology and he discussed the changing opinions regarding the utilization of radical cystectomy in the aging population.

SUO 2018: Role of Trimodality and Comparison with Cystectomy in Muscle Invasive Bladder Cancer

Phoenix, Arizona ( The ideal candidate for bladder preservation in patients with muscle invasive urothelial carcinoma is often debated, as is the overall of efficacy of bladder preservation with trimodal therapy compared to radical cystectomy. As part of the Bladder Cancer session at the 2018 annual meeting of the Society of Urologic Oncology, Dr. Alexandre Zlotta from the University of Toronto provided his thoughts on this controversial topic.

SUO 2018: DNA Damage Response – ADT + PARPi

Phoenix, Arizona ( Increased understanding of the genomic landscape of advanced and metastatic prostate cancer has led to potentially actionable targets. Pritchard et al. demonstrated that 12% of men with advanced or mPCa has germline mutations in DNA repair genes. This was irrespective of family history and age of onset. BRCA2 was most common, but there were numerous that accounted for just 1-2% of that 12%. 


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.